ARCHIVES

Amgen Claimed QOL Benefit Despite FDA Label Change.

This article is from The Cancer Letter archive.

Vol. 33 No. 19 | May 18, 2007

Download PDF Visit The Full Archive

Related Articles

Edelson To Step Down As Yale Center Director.

January 11, 2008

In Brief: NCHSR Says Autologous Marrow Transplant Is A “Reasonable Therapeutic Alternative”

August 11, 1989

ASCO Survey Finds Practice Expenses 90% Higher Than Medicare Assumptions

October 11, 2002

Sloan-Kettering Creates Paul Marks Award; Weinberg, Hong Honored By M. D. Anderson.

February 18, 2000

Two Conflicting Studies Presented at ASCO 2013, FDA Called Upon To Sort Through The Data

June 28, 2013

In Brief: UICC Publishes International directory Of Cancer Centers; HSAs Still Worry NCI

January 7, 1977